Literature DB >> 31445353

Deletion of interleukin-18 attenuates abdominal aortic aneurysm formation.

Chika Suehiro1, Jun Suzuki2, Mika Hamaguchi1, Kayo Takahashi1, Tomoaki Nagao1, Tomoki Sakaue3, Teruyoshi Uetani1, Jun Aono1, Shuntaro Ikeda1, Takafumi Okura3, Haruki Okamura4, Osamu Yamaguchi1.   

Abstract

BACKGROUND AND AIMS: Abdominal aortic aneurysm (AAA) is a common disease; however, its exact pathogenesis remains unknown, and no specific medical therapies are available. Interleukin (IL)-18 plays a crucial role in atherosclerotic plaque destabilization and is a strong predictor of cardiovascular death. Here, we investigated the role of IL-18 in AAA pathogenesis using an experimental mouse model. METHODS AND
RESULTS: After infusion of angiotensin II (Ang II) for 4 weeks and β-aminopropionitrile (BAPN) for 2 weeks, 58% of C57/6J wild-type (WT) mice developed AAA associated with enhanced expression of IL-18; however, disease incidence was significantly lower in IL-18-/- mice than in WT mice (p < 0.01), although no significant difference was found in systolic blood pressure between WT mice and IL-18-/- mice in this model. Additionally, IL-18 deletion significantly attenuated Ang II/BAPN-induced macrophage infiltration, macrophage polarization into inflammatory M1 phenotype, and matrix metalloproteinase (MMP) activation in abdominal aortas, which is associated with reduced expression of osteopontin (OPN).
CONCLUSIONS: These findings indicate that IL-18 plays an important role in the development of AAA by enhancing OPN expression, macrophage recruitment, and MMP activation. Moreover, IL-18 represents a previously unrecognized therapeutic target for the prevention of AAA formation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm; Interleukin-18; Macrophage; Matrix metalloproteinase; Osteopontin

Mesh:

Substances:

Year:  2019        PMID: 31445353     DOI: 10.1016/j.atherosclerosis.2019.08.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study.

Authors:  Philipp Jud; Nicolas Verheyen; Martin H Stradner; Christian Dejaco; Dieter Szolar; René Thonhofer; Leyla Schweiger; Marianne Brodmann; Franz Hafner
Journal:  Rheumatol Int       Date:  2022-08-23       Impact factor: 3.580

Review 2.  Twenty Years of Studying AngII (Angiotensin II)-Induced Abdominal Aortic Pathologies in Mice: Continuing Questions and Challenges to Provide Insight Into the Human Disease.

Authors:  Hisashi Sawada (澤田悠); Hong S Lu (吕红); Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-01-20       Impact factor: 8.311

3.  MiR-191 as a Key Molecule in Aneurysmal Aortic Remodeling.

Authors:  Sabina Lichołai; Dorota Studzińska; Hanna Plutecka; Tomasz Gubała; Wojciech Szczeklik; Marek Sanak
Journal:  Biomolecules       Date:  2021-10-30

Review 4.  Development of pharmacotherapies for abdominal aortic aneurysms.

Authors:  Lauren M Weaver; Charles D Loftin; Chang-Guo Zhan
Journal:  Biomed Pharmacother       Date:  2022-06-30       Impact factor: 7.419

Review 5.  Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms.

Authors:  Jinyun Shi; Jia Guo; Zhidong Li; Baohui Xu; Masaaki Miyata
Journal:  J Atheroscler Thromb       Date:  2021-03-06       Impact factor: 4.928

6.  Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice.

Authors:  Akimichi Saito; Naoki Ishimori; Satoshi Tokuhara; Tsuneaki Homma; Mikito Nishikawa; Kazuya Iwabuchi; Hiroyuki Tsutsui
Journal:  Front Cardiovasc Med       Date:  2021-05-10

Review 7.  Induction of thoracic aortic dissection: a mini-review of β-aminopropionitrile-related mouse models.

Authors:  Hai-Qiong Zheng; Jia-Bing Rong; Fei-Ming Ye; Yin-Chuan Xu; Hong S Lu; Jian-An Wang
Journal:  J Zhejiang Univ Sci B       Date:  2020 Aug.       Impact factor: 5.552

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.